Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients

British Journal of Clinical Pharmacology

Volumn 48, Issue 2, 1999, Pages 168-179

  Gallicano, Keith D ^a,c   Sahai, Jan ^b   Shukla, Vijay K ^b   Seguin, Isabelle ^b   Pakuts, Attila ^a   Kwok, David ^d   Foster, Brian C ^a   Cameron, D William ^c  

^a Bureau of Drug Research   (Canada)

^b Clinical Investigation Unit   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d HEALTH CANADA   (Canada)

Author keywords

3' Amino 3' deoxythymidine; Drug interaction; Induction; Pharmacokinetics; Rifampicin; Zidovudine

Indexed keywords

RIFAMPICIN; ZIDOVUDINE;

ADULT; AMINATION; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG GLUCURONIDATION; DRUG URINE LEVEL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADULT; AMINES; ANTI-HIV AGENTS; ANTIBIOTICS, ANTITUBERCULAR; AREA UNDER CURVE; BIOTRANSFORMATION; DRUG INTERACTIONS; FEMALE; GLUCURONATES; HALF-LIFE; HIV INFECTIONS; HUMANS; MALE; RIFAMPIN; ZIDOVUDINE;

EID: 0032775776     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00987.x     Document Type: Article

References (34)

1. 1 Drobniewski F. Is death inevitable with multiresistant TB plus HIV infection? Lancet 1997; 349: 71-72.
2. 2 Burman WJ, Gallicano K, Peloquin C. Therapeutic implications of drug interactions in the treatment of HIV-related tuberculosis. Clin Infect Dis 1999; 28: 419-430.
3. 3 Centers for Disease Control and Prevention. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR Morb Mortal Wkly Rep 1998 47 (no. RR-20): 11-15.
4. 4 Veal GJ, Back DJ. Metabolism of zidovudine. General Pharmacol 1995; 26: 1469-1475.
5. 5 Cretton EM, Xie M, Bevan RJ, Goudgaon NM, Schinazi RF, Sommadossi J-P. Catabolism of 3′-azido 3′ deoxythymidine in hepatocytes and liver enzymes with evidence of formation of 3′-amino-3′-deoxythymidine, a highly toxic catabolic for human bone marrow cells. Mol Pharmacol 1990; 39: 258-266.
6. 6 Stagg MP, Cretton EM, Kidd L, Diasio RB, Sommadossi J-P. Clinical pharmacokinetics of 3′-azido-3′-deoxythymidine (zidovudine) and catabolites with formation of a toxic catabolic, 3′-amino-3′-deoxythymidine. Clin Pharmacol Ther 1992; 51: 668-676.
7. 7 Rajaonarison JF, Lacarelle B, De Sousa G, Catalin J, Rahmani R. In vitro glucuronidation of 3′-azido-3′-deoxythymidine by human liver. Role of UDP-glucuronosyltransferase 2 form. Drug Metab Dispos 1991; 19: 809-815.
8. 8 Pan-Zhou XR, Cretton-Scott L, Zhou XJ, Yang MX, Lasker JM, Sommadossi J-P. Role of human liver P450s and cytochrome b5 in the reductive metabolism of 3′-azido-3′-deoxythymidine (AZT) to 3′-amino-3′-deoxythymidine. Biochem Pharmacol 1998; 55: 757-766.
9. 9 Cretton EM, Sommadossi J-P. Reduction of 3′-azido-2′,3′-dideoxynucleosides to their 3′-amino metabolite is mediated by cytochrome P 450 and NADPH cytochrome P 450 reductase in rat liver microsomes. Drug Metab Dispos 1993; 21: 946-950.
10. 10 Eagling VA, Howe JL, Barry MJ, Back DJ. The metabolism of zidovudine by human liver microsomes in vitro: formation of 3′-amino-3′-deoxythymidine. Biochem Pharmacol 1994; 48: 267-276.
11. 11 Oesch F, Arand M, Strolin Benedetti MS, Castelli MG, Dostert P. Inducing properties of rifampicin and rifabutin for selected enzyme activities of the cytochrome P-450 and UDP-glucuronosyltransferase superfamilies in female rat liver. J Antimicrob Chemother 1996; 37: 1111-1119.
12. 12 Adachi Y, Nanno T, Yamashita M, Ueshima S, Yamamoto T. Induction of rat liver bilirubin-conjugating enzymes and glutathione S-transferase by rifampicin. Gastroenterol Jpn 1985; 20: 104-110.
13. 13 Constantopoulos A, Loupa H, Krikos X. Augmentation of hepatic uridine-diphosphate glucuronyl transferase activity by antituberculosis drugs in hamsters in vivo. Cytobios 1987; 52: 185-189.
14. 14 Doostdar H, Grant MH, Melvin WT, Wolf CR, Burke MD. The effects of inducing agents on cytochrome P 450 and UDP glucuronyltransferase activities in human hepG2 hepatoma cells. Biochem Pharmacol 1993; 46: 629-635.
15. 15 Abid A, Sabolovic N, Magdalou J. Inducibility of ethoxyresorufin deethylase and UDP-glucuronosyltransferase activities in two human hepatocarcinoma cell lines KYN 2 and Mz-Hep-1. Cell Biol Toxicol 1996; 12: 115-123.
16. 16 Burger DM, Meenhorst PL, Koks CHW, Beijnen JH. Pharmacokinetic interaction between rifampin and zidovudine. Antimicrob Agents Chemother 1993; 37: 1426-1431.
17. 17 Strolin Benedetti M, Duchene P, Olliaro P. Investigation on a possible induction of AZT glucuronidation by rifabutin and rifampicin in humans. In Proceedings of the Third International Society for the Study of Xenobiotics Meeting; June 1991 Amsterdam. Book of Abstracts, 295.
18. 18 Strolin-Benedetti M, Dostert P. Induction and autoinduction properties of rifamycin derivatives: a review of animal and human studies. Environ Health Perspectives 1994; 102(Suppl 9): 101-105.
19. 19 Swart KJ, Papgis M. Automated high-performance liquid Chromatographic method for the determination of rifampicin in plasma J Chromatogr 1992; 593: 21-24.
20. 20 Burger DM, Rosing H, Koopman FJ, et al. Determination of 3′-amino-3′-deoxythymidine, a cytotoxic metabolite of 3′-azido-3′-deoxythymidine, in human plasma by ion-pair high-performance liquid chromatography. J Chromatogr 1993; 622: 235-242.
21. 21 Good SS, Reynolds DJ, de Miranda P. Simultaneous quantification of zidovudine and its glucuronide in serum by high-performance liquid chromatography. J Chromatogr 1988; 431: 123-133.
22. 22 Li AP, Reith MK, Rasmussen A, et al. Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin. Chem Biol Interact 1997; 107: 17-30.
23. 23 Hoetelmans RMW, Meenhorst PL, Mulder JW, Burger DM, Koks CHW, Beijnen JH. Plasma pharmacokinetics of 3′-amino-3′-deoxythymidine, a cytotoxic metabolite of zidovudine [Abstract Mo. B. 1324]. XI International Conference on AIDS; July 1996 Vancouver.
24. 24 Zhou XJ, Sommadossi J-P. Comparative pharmacokinetics of zidovudine and its toxic catabolic 3′-amino-3′-deoxythymidine in HIV-infected patients. AIDS Res Hum Retroviruses 1996; 12: 229-233.
25. 25 Sahai J, Gallicano K, Garber G, Pakuts A, Cameron W. Pharmacokineties of simultaneously administered zidovudine and didanosine in HIV-seropositive male patients. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10: 54-60.
26. 26 Gallicano K, Sahai J, Swick L, Seguin I, Pakuts A, Cameron DW. Effect of rifabutin on the pharmacokinetics of zidovudine in patients infected with human immunodeficiency virus. Clin Infec Dis 1995; 21: 1008-1011.
27. 27 Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of P-glycoprotein and cytochrome P 4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 1996; 49: 311-318.
28. 28 Glynn SL, Yazdanian M. In vitro blood-brain barrier permeability of nevirapine compared to other antiretroviral agents. J Pharm Sci 1998; 87: 306-310.
29. 29 Howe JL, Back DJ, Colbert J. Extrahepatic metabolism of zidovudine. Br J Clin Pharmacol 1992; 33: 190-192.
30. 30 Fayz S, Inaba T. Zidovudine azido-reductase in human liver microsomes: activation by ethacrynic acid, dipyridamole, and indomethacin and inhibition by human immunodeficiency virus protease inhibitors. Antimicrob Agents Chemother 1998; 42: 1654-1658.
31. 31 Burchell B, Brierley CH, Rance D. Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation. Life Sci 1995; 57: 1819-1831.
32. 32 Antoniskis D, Easley AC, Espina BM, Davidson PT, Barnes PF. Combined toxicity of zidovudine and antituberculosis chemotherapy. Am Rev Respir Dis 1992; 145: 430-434.
33. 33 Collier AC, Bozzette S, Coombs RW, et al. A pilot study of low dose zidovudine in human immunodeficiency virus infection. N Engl J Med 1990; 323: 1015-1021.
34. 34 Barry MG, Khoo SH, Veal GJ, et al. The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites. AIDS 1996; 10: 1361-1367.